Home » Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients
Exelixis Zeroes in on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients
Exelixis gambled a little more than a year ago, deciding to go “all-in” on its lead drug candidate for cancer after many investors lost interest in its strategy of building a broad pipeline with lots of different drugs.
Xconomy
Xconomy
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May